ADVERTISEMENT
Advertise

Content

List volumes - List articles in this issue

Letter to the Editor

Mycosis Fungoides with Recurrent Hodgkin’s Lymphoma and Diffuse Large B-cell Lymphoma

doi: 10.2340/00015555-0663

Abstract:

Abstract is missing (Letter)

Authors:

Tomomitsu Miyagaki, Makoto Sugaya, Yosaku Minatani, Hideki Fujita, Akira Hangaishi, Mineo Kurokawa, Yutaka Takazawa and Kunihiko Tamaki

References

  • Huang KP, Weinstock MA, Clarke CA, McMillan A, Hoppe RT, Kim YH. Second lymphomas and other malignant neoplasms in patients with mycosis fungoides and Sézary syndrome: evidence from population-based and clinical cohorts. Arch Dermatol 2007; 143: 45–50.
  • Väkevä L, Pukkala E, Ranki A. Increased risk of secondary cancers in patients with primary cutaneous T cell lymphoma. J Invest Dermatol 2000; 115: 62–65.
  • Hallermann C, Kaune KM, Tiemann M, Kunze E, Griesinger F, Mitteldorf C, et al. High frequency of primary cutaneous lymphomas associated with lymphoproliferative disorders of different lineage. Ann Hematol 2007; 86: 509–515.
  • Mauch PM, Kalish LA, Marcus KC, Coleman CN, Shulman LN, Krill E, et al. Second malignancies after treatment for laparotomy staged IA-IIIB Hodgkin’s disease: long-term analysis of risk factors and outcome. Blood 1996; 87: 3625–3632.
  • Ng AK, Bernardo MV, Weller E, Backstrand K, Silver B, Marcus KC, et al. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood 2002; 100: 1989–1996.
  • van Leeuwen FE, Klokman WJ, Hagenbeek A, Noyon R, van den Belt-Dusebout AW, van Kerkhoff EH, et al. Second cancer risk following Hodgkin’s disease: a 20-year follow-up study. J Clin Oncol 1994; 12: 312–325.
  • Beylot-Barry M, Dubus P, Vergier B, Cogrel O, Marit G, Beylot C, et al. Meningeal involvement by a transformed mycosis fungoides following Hodgkin’s disease. Br J Dermatol 1999; 141: 909–913.
  • Grange F, Avril MF, Esteve E, Joly P, Bosq J, de Murets A, et al. Coexistent cutaneous T-cell lymphoma and B-cell malignancy. French Study Group on Cutaneous Lymphomas. J Am Acad Dermatol 1994; 31: 724–731.
  • Weiss VC, Barsky GJ, Solomon LM. Cutaneous T-lymphocyte lymphoma in association with multiple myeloma. Arch Dermatol 1984; 120: 499–501.
  • Kikuchi A, Anzai H, Kosuge H, Naka W, Nishikawa T. Aggressive B-cell lymphoma induced by Epstein-Barr virus infection in erythrodermic cutaneous T-cell lymphoma. Br J Dermatol 1997; 136: 124–128.
  • Peterman A, Jerdan M, Staal S, Bender B, Striecher H, Schüpbach J, et al. Evidence for HTLV-I associated with mycosis fungoides and B-cell chronic lymphocytic leukemia. Arch Dermatol 1986; 122: 568–571.
  • Sheibani K, Forman SJ, Winberg CD, Rappaport H. Coincidence of B-cell chronic lymphocytic leukemia and cutaneous T-cell lymphoma (mycosis fungoides): immunologic characterization by monoclonal antibodies. Blood 1983; 62: 1176–1181.
  • Bennett MH, MacLennan KA, Vaughan Hudson G, Vaughan Hudson B. Non-Hodgkin’s lymphoma arising in patients treated for Hodgkin’s disease in the BNLI: a 20-year experience. British National Lymphoma Investigation. Ann Oncol 1991; 2: 83–92.
  • Lee BN, Duvic M, Tang CK, Bueso-Ramos C, Estrov Z, Reuben JM. Dysregulated synthesis of intracellular type 1 and type 2 cytokines by T cells of patients with cutaneous T-cell lymphoma. Clin Diagn Lab Immunol 1999; 6: 79–84.
  • Gniadecki R. Neoplastic stem cells in cutaneous lymphomas: evidence and clinical implications. Arch Dermatol 2004; 140: 1156–1160.
  • Related articles

    There are no related articles.


    Share with your friends





    Actions


    Abstract

    Full text

    PDF

    Supplementary


    There is no supplementary for this article.

    Print information


    Volume 89, Issue 4

    DOI: 10.2340/00015555-0663

    Pages: 421-422

    View at PubMed